

Influenza & Coronavirus Pandemic Preparedness Asia 2013

Asia's only conference on pandemic preparedness strategies, public-private partnerships and vaccines development for influenza & coronavirus

23 - 24 October 2013 | Traders Hotel, Singapore

CONFERENCE DAY ONE: 23rd October 2013 | Wednesday

0900 Chairperson's Opening Remarks

Prof. Richard Coker, Professor of Public Health, **London School of Hygiene and Tropical Medicine**; Head - **Communicable Diseases Policy Research Group (CDPRG)**, Thailand; Visiting Professor, Head - ID Programme, Saw Swee Hock School of Public Health, **National University of Singapore**, Singapore

Updates on Influenza Vaccines & Management

0910 Review of H7N9 Avian Influenza Virus

- Characterization of H7N9 virus
- Challenges to development of the vaccine for H7N9
- Safety and efficacy of the vaccine
- Diagnostics for H7N9

Dr. Masato Tashiro, Director – Center for Influenza Virus Research, **WHO Collaborating Centre for References & Research on Influenza**, **National Institute of Infectious Diseases**, Japan

0945 Recombinant Nanoparticle Vaccines for MERS and H7N9: Review of Progress and Plans Forward

- Review of progress on development of recombinant H7N9 vaccine
- Review of progress on development of recombinant MERS coronavirus vaccine
- Overview of path forward for Novavax' recombinant vaccines for both emerging threats

Dr. Gregory M. Glenn, M.D., Senior Vice President & Chief Medical Officer, **Novavax, Inc.**, USA

1015 Morning Refreshments

Regional Pandemic Preparedness Strategy & Influenza Surveillance Updates

1045 Mitigation Strategies and Pandemic Influenza Preparedness in South East Asia

- How well are we prepared for the next pandemic?
- How can we manage uncertainties?
- Where should we invest?

Prof. Richard Coker, Professor of Public Health, **London School of Hygiene and Tropical Medicine**; Head - **Communicable Diseases Policy Research Group (CDPRG)**, Thailand; Visiting Professor, Head - ID Programme, Saw Swee Hock School of Public Health, **National University of Singapore**, Singapore

1120 Malaysia's Updates on Pandemic Preparedness Initiatives and Strategies

Dr. Chong Chee Kheong, Director, Disease Control Division, **Ministry of Health Malaysia**, Malaysia

1155 Molecular Methods in Diagnostics and Managing Pandemics

- Needs for diagnostic testing in epidemic situation
- Use of diagnostic tests for personalised medicine
- Key requirements from these tests
- Benefits of these requirements for patient management

Dr. Bhuvnesh Agrawal, MD, PhD, MBA, Head of APAC and global CMO Internal Med, Clin Pharmacol, Pharmacol & Tox, **Vela Holding Pte. Ltd**, Singapore

1225 Networking Lunch

1340 Updates from Mekong Basin Disease Surveillance Network: China, Cambodia, Lao, Myanmar, Thailand & Vietnam

- Updates and current initiatives of MBDS in influenza and EID surveillance
- Recent advancements and innovations
- MBDS's responses TO 2009 Novel H1N1: Lessons learnt

Dr. Moe Ko Oo, Board Member and Head of Secretariat, Mekong Basin Disease Surveillance Foundation, Thailand

1415 Bioinformatics in Influenza Surveillance

- Benefits of adding bioinformatics to emerging infectious disease surveillance
- Case studies: Influenza H1N1 pandemic, H7N9 and MERS-CoV
- How bioinformatics can fit into a national/regional pandemic preparedness plan?

Dr. Sebastian Maurer-Stroh, Senior Principal Investigator, Programme Director Human Infectious Diseases, Bioinformatics Institute, A*STAR, Singapore

1450 Application of Next Generation Sequencing Technology for Rapid Identification and Tracking of China's Recent H7N9 Outbreak

This presentation will feature Illumina's Next Generation sequencing technology, which was used in collaboration with Jiangsu Province Centre for Disease Control (CDC) to identify and track the potential source of the most recent H7N9 outbreak. The New England Journal of Medicine and Lancet articles that published the results of this collaboration will also be discussed as well, to highlight the molecular epidemiology, pathogen identification and transmission path reconstruction of this infection. Other examples of how Illumina's MiSeq™ technology could be used in national bio-surveillance and public health initiatives will also be discussed.

Dr. Arjuna Kumarasuriyar, District Sales Manager, South Asia, Illumina, Singapore

1520 Afternoon Refreshments

1550 Management of Influenza A H7N9

Dr. Hsueh Po Ren, Chief of Division of Clinical Microbiology, Department of Laboratory Medicine, National Taiwan University Hospital (NTUH), Taiwan

Animal Health Surveillance

1625 Indonesia's Updates on Strategic Plans and Initiatives for Animal Disease Detection & Surveillance: Current Updates and Best Practices

Dr. Syafrison Idris, Head of Animal Disease Investigation Section, Directorate of Animal Health, DGLAHS Indonesia, Indonesia

1700 Vietnam's Animal Health Surveillance System & Vaccination Strategies for Pandemic Preparedness

Dr. Van Dang Ky, DVM, Ph.D, Chief of Epidemiology Division, Department of Animal Health, Vietnam

1735 Chairperson's Remarks and End of Conference Day One

LmPi

Hsueh SM

Handwritten calculations: 2, 52, 1250, 120, 50

Handwritten calculations: 52, 134, 208, 104

Handwritten circled numbers 2, 6, 4

Handwritten number 8

Handwritten number 9

Handwritten number 10

Handwritten numbers 310, 306

Handwritten numbers 316, 310

Influenza & Coronavirus Pandemic Preparedness Asia 2013

Asia's only conference on pandemic preparedness strategies, public-private partnerships and vaccines development for influenza & coronavirus

23 - 24 October 2013 | Traders Hotel, Singapore

CONFERENCE DAY TWO: 24th October 2013 | Thursday

0900 Chairperson's Remarks

Prof. Richard Coker, Professor of Public Health, London School of Hygiene and Tropical Medicine; Head - Communicable Diseases Policy Research Group (CDPRG), Thailand; Visiting Professor, Head - ID Programme, Saw Swee Hock School of Public Health, National University of Singapore, Singapore

Building up Capacity for Pandemic Preparedness

0910 Economics and Multi-Sectoral Collaboration for Infectious Disease Preparedness

- Economic impact of ID and flu, cost-effectiveness of interventions
- Need for multi-sectoral collaboration and whole of society approach

Dr. Vernon Lee, Adjunct Associate Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore

Developing Vaccines & Diagnostics for Pandemic Preparedness

0950 [Perspectives of IFPMA] Vaccines Access & Supply: Ensuring the Availability of Vaccines During the Pandemic

Dr William Cracknell, Chair, Influenza Vaccines Supply International Task Force, IFPMA; Director, Influenza Development & Innovation, CSL, Australia

1030 Morning Refreshments

1100 Flu Vaccines based on VLP technology

Flu vaccines are not available in time of novel epidemics. Standardized technologies should be made available that allow R&D as well as manufacturing in a short time, with high quality and at reasonable prices. Investigational medicine Units allow for fast and GCP-compliant testing of immunogenicity. Challenge units would allow early proof-of-concept in terms of protection. The VLP technology is a possible way out of the dilemma requiring no live virus, no eggs and no mammalian cell culture. A candidate vaccine must be produced at risk as soon as a relevant virus has been isolated, independent of proven human-human transmission.

Dr. Alex Matter, M.D., CEO, Experimental Therapeutics Centre & D3, A*STAR, Singapore

1140 Vaccination against Avian Influenza as an Aid to Eradication

John Walters, Senior Director Poultry Asia Pacific, Zoetis, Singapore

1220 Networking Lunch

- 4
- 1320 **Preparedness against Potential Entry of Novel Influenza Virus via Rapid Development of Diagnostics Assays**
- Review of current capabilities and gaps of diagnostics for influenza, recent advances and innovations
 - A*Star's development of assay for H7N9 virus based on viral sequences released by GISAID on 31st of March
 - Hints about how to optimise a multiplex diagnostic assay to subtype fluA, pH1N1, H3N2, nH7N9, H5N1 and FluB without compromising assay performance
- Dr. Masafumi Inoue, Group Leader, Molecular Diagnostics Group, **Experimental Therapeutics Center (ETC), A*STAR**, Singapore
- 2-10
92
93

Planning and Infection Control

- 5
- 1400 **[Case Study] Disease Surveillance and Infection Control in a Hospital Setting**
- Devising an infection control plan for new virus on short notice: How does it work?
 - Best practices in minimizing contamination and human errors in a healthcare facility
 - Case study experience: From receiving warning by health authorities to completing preparedness plan
- Dr. Ling Moi Lin, Senior Consultant, Director of Infection Control, **Singapore General Hospital & President, Asia Pacific Society of Infection Control**, Singapore
- 2-10
102

- 6
- 1440 **Pandemic Preparedness: The Perspective of a Public Hospital Laboratory**
- Case study experience and planning during the inter-pandemic period
- Dr. Nancy Tee, Head of the Department of Pathology and Laboratory Medicine, **KK Women's and Children's Hospital**, Singapore
- 2-10
124
125

- 1520 **Chairperson's Closing Remarks followed by Afternoon Refreshments**